The prognostic value of apoptotic and proliferative markers in breast cancer

Ki67 and proliferation in breast cancer

(2013) Nirmala Pathmanathan et al.   JOURNAL OF CLINICAL PATHOLOGY

New Insight into Ki67 Expression at the Invasive Front in Breast Cancer

(2013) Peng Gong et al.   PLoS One

Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K–AKT, Wnt/β-catenin and P53 pathway activation

(2012) Remi A. Nout et al.   GYNECOLOGIC ONCOLOGY

Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers

(2011) S. J. Kim et al.   ANNALS OF ONCOLOGY

Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer

(2011) E C M Zeestraten et al.   BRITISH JOURNAL OF CANCER

Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer

(2011) Christine Nyiraneza et al.   HUMAN PATHOLOGY

COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients

(2010) Johanna G. H. van Nes et al.   BREAST CANCER RESEARCH AND TREATMENT

The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer

(2010) E. M. de Kruijf et al.   CLINICAL CANCER RESEARCH

Current and emerging biomarkers in breast cancer: prognosis and prediction

(2010) Marion T Weigel et al.   ENDOCRINE-RELATED CANCER

Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients

(2009) J G H van Nes et al.   BRITISH JOURNAL OF CANCER

Rethinking Screening for Breast Cancer and Prostate Cancer

(2009) Laura Esserman   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION